Immutep Ltd (LSX:A2H8YL) Filings

Immutep Ltd

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 19, 2026Current reportSEC
Encouraging Disease-Free Survival in Phase II Sarcoma TrialNov 18, 2026Operations updateASX
Immutep Investor UpdateNov 17, 2026Other filingsASX
Immutep Expands US Patents for Efti Combination TherapiesNov 10, 2026Other filingsASX
EFTISARC-NEO Survival Data reported in CTOS 2026 AbstractNov 10, 2026Operations updateASX
6-K · Report of a foreign issuerNov 10, 2026Current reportSEC
IMP761 Late-Breaking Abstract at ACR shows T-Cell InhibitionNov 8, 2026Operations updateASX
Upcoming Poster Presentations at CTOS and ESMO IO 2026Nov 4, 2026Other filingsASX
6-K · Report of a foreign issuerOct 30, 2026Current reportSEC
6-K · Report of a foreign issuerOct 29, 2026Current reportSEC
Immutep Quarterly Activities Report and Appendix 4COct 28, 2026Quarterly reportASX
Immutep Receives A$2.16 million French R&D Tax IncentiveOct 27, 2026FinancingASX
Notice of Annual General Meeting/Proxy FormOct 26, 2026Meeting noticeASX
Appendix 4G and Corporate Governance StatementOct 26, 2026Other filingsASX
Annual Report to shareholdersOct 26, 2026Annual reportASX
Annual Report filed on Form 20-FOct 25, 2026Annual reportASX
20-F · Annual reportOct 23, 2026Annual reportSEC
Quality of Life Data from EFTISARC-NEO presented at ESMOOct 23, 2026Operations updateASX
Late-Breaking Abstract on IMP761 to be presented at ACR 2026Oct 18, 2026Other filingsASX
2026 Annual General Meeting and Key DatesOct 14, 2026Meeting noticeASX
6-K · Report of a foreign issuerOct 13, 2026Current reportSEC
Immutep & Monash Secure Further ARC Funding for LAG-3Oct 13, 2026Other filingsASX
Immutep Regains Compliance with NasdaqOct 12, 2026Compliance certificateASX
Audit and Risk Committee UpdateOct 9, 2026Other filingsASX
Final Director's Interest Notice - P MeyersOct 4, 2026List of directorsASX
Notification of cessation of securities - IMMOct 4, 2026FinancingASX
Resignation of Non-Executive DirectorOct 4, 2026Management or board changeASX
Change of Director's Interest Notice - P MeyersSep 30, 2026Ownership change noticeASX
Application for quotation of securities - IMMSep 30, 2026FinancingASX
Immutep receives Australian R&D Tax IncentiveSep 29, 2026FinancingASX
6-K · Report of a foreign issuerSep 22, 2026Current reportSEC
6-K · Report of a foreign issuerSep 11, 2026Current reportSEC
Immutep Outlines Focused Development Strategy for EftiSep 10, 2026Operations updateASX
S&P DJI Announces September 2026 Quarterly RebalanceSep 4, 2026Other filingsASX
6-K · Report of a foreign issuerSep 1, 2026Current reportSEC
Appendix 4E & 2026 Full Year Statutory AccountsAug 30, 2026Annual reportASX
Immutep Corporate PresentationAug 19, 2026Other filingsASX
6-K · Report of a foreign issuerJul 31, 2026Current reportSEC
Immutep Quarterly Activities Report and Appendix 4CJul 29, 2026Quarterly reportASX
6-K · Report of a foreign issuerJul 13, 2026Current reportSEC
6-K · Report of a foreign issuerJun 4, 2026Current reportSEC
UPLOAD · Letter from the SECMay 11, 2026Other filingsSEC
6-K · Report of a foreign issuerMay 1, 2026Current reportSEC
6-K · Report of a foreign issuerApr 30, 2026Current reportSEC
CORRESP · Letter to the SECApr 24, 2026Other filingsSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
6-K · Report of a foreign issuerApr 15, 2026Current reportSEC
Immutep receives FDA ODD for Efti in Soft Tissue SarcomaApr 14, 2026Operations updateASX
3 · Initial statement of ownershipApr 13, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 13, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 7, 2026Insider tradeSEC
UPLOAD · Letter from the SECApr 7, 2026Other filingsSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 19, 2026Current reportSEC
Update on Phase I Study of IMP761 for Autoimmune DiseasesMar 18, 2026Other filingsASX
6-K · Report of a foreign issuerMar 16, 2026Current reportSEC
Reinstatement to QuotationMar 12, 2026Trading halt or suspensionASX
TACTI-004 to be discontinued following futility analysisMar 12, 2026Operations updateASX
Suspension from QuotationMar 10, 2026Trading halt or suspensionASX
Trading HaltMar 6, 2026Trading halt or suspensionASX
6-K · Report of a foreign issuerFeb 25, 2026Current reportSEC
Half Yearly Report and AccountsFeb 24, 2026Interim reportASX
6-K · Report of a foreign issuerFeb 9, 2026Current reportSEC
Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLCFeb 5, 2026Operations updateASX
6-K · Report of a foreign issuerJan 29, 2026Current reportSEC
Immutep Quarterly Activities Report and Appendix 4CJan 29, 2026Quarterly reportASX
6-K · Report of a foreign issuerDec 22, 2025Current reportSEC
Positive Update on IMP761 Phase 1Dec 21, 2025Operations updateASX
6-K · Report of a foreign issuerDec 16, 2025Current reportSEC
TACTI-004 phase III trial enrolment continues at robust paceDec 15, 2025Operations updateASX
6-K · Report of a foreign issuerDec 9, 2025Current reportSEC
Immutep enters into Strategic Collaboration with Dr. Reddy'sDec 8, 2025Acquisition or disposalASX
6-K · Report of a foreign issuerDec 2, 2025Current reportSEC
New data presentation from AIPAC-003 Phase II for SABCSDec 1, 2025Operations updateASX
6-K · Report of a foreign issuerNov 13, 2025Current reportSEC
EFTISARC-NEO Phase II results presented at CTOS 2025Nov 12, 2025ResultsASX
6-K · Report of a foreign issuerNov 3, 2025Current reportSEC
Immutep Receives A$4.6 million French R&D Tax IncentiveNov 2, 2025FinancingASX
6-K · Report of a foreign issuerOct 30, 2025Current reportSEC
20-F · Annual reportOct 24, 2025Annual reportSEC
6-K · Report of a foreign issuerOct 21, 2025Current reportSEC
6-K · Report of a foreign issuerOct 20, 2025Current reportSEC
Primary Endpoint Met in STS Trial - presented at ESMO 2025Oct 19, 2025ResultsASX
Improved ORR in First Line NSCLC - presented at ESMO 2025Oct 19, 2025Other filingsASX
6-K · Report of a foreign issuerOct 14, 2025Current reportSEC
Successful Completion of FDA Project Optimus RequirementsOct 12, 2025Operations updateASX
6-K · Report of a foreign issuerOct 9, 2025Current reportSEC
TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLCOct 8, 2025Other filingsASX
6-K · Report of a foreign issuerSep 22, 2025Current reportSEC
New investigator-initiated Phase II trial for EftiSep 21, 2025Operations updateASX
6-K · Report of a foreign issuerSep 2, 2025Current reportSEC
Appendix 4E & 2025 Full Year Statutory AccountsAug 28, 2025Annual reportASX
6-K · Report of a foreign issuerAug 6, 2025Current reportSEC
FDA feedback received for head & neck cancer in CPS below 1Aug 4, 2025Other filingsASX
6-K · Report of a foreign issuerJul 30, 2025Current reportSEC
6-K · Report of a foreign issuerJun 23, 2025Current reportSEC
6-K · Report of a foreign issuerMay 27, 2025Current reportSEC
Primary Endpoint Met in Phase II Soft Tissue Sarcoma TrialMay 25, 2025Operations updateASX
6-K · Report of a foreign issuerMay 15, 2025Current reportSEC
High Response Rates achieved in Lung Cancer in INSIGHT-003May 14, 2025Operations updateASX
6-K · Report of a foreign issuerMay 5, 2025Current reportSEC
Excellent Overall Survival in Head & Neck Cancer PatientsMay 4, 2025ResultsASX
6-K · Report of a foreign issuerApr 29, 2025Current reportSEC
6-K · Report of a foreign issuerMar 25, 2025Current reportSEC
First patient dosed in phase 3 TACTI-004 lung cancer trialMar 24, 2025Operations updateASX
6-K · Report of a foreign issuerFeb 27, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 3, 2025Current reportSEC
6-K · Report of a foreign issuerDec 17, 2024Current reportSEC
Immutep announces initial safety data from IMP761 phase 1Dec 16, 2024Operations updateASX
6-K · Report of a foreign issuerDec 12, 2024Current reportSEC
Immutep Reports Promising New Data in Head and Neck CancerDec 11, 2024ResultsASX
6-K · Report of a foreign issuerDec 10, 2024Current reportSEC
Initiation of TACTI-004 phase 3 trial in 1st line NSCLCDec 9, 2024Operations updateASX
6-K · Report of a foreign issuerNov 15, 2024Current reportSEC
6-K · Report of a foreign issuerNov 14, 2024Current reportSEC
Excellent Survival Data from INSIGHT-003 Trial in NSCLCNov 13, 2024ResultsASX
Positive Data from Phase II Trial in Soft Tissue SarcomaNov 13, 2024Other filingsASX
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerOct 29, 2024Current reportSEC
20-F · Annual reportOct 22, 2024Annual reportSEC
6-K · Report of a foreign issuerOct 3, 2024Current reportSEC
Enrolment for Ph II AIPAC-003 Breast Cancer Trial CompletedOct 3, 2024Other filingsASX
6-K · Report of a foreign issuerSep 24, 2024Current reportSEC
Immutep receives A$3.6 million French R&D Tax IncentiveSep 23, 2024Other filingsASX
6-K · Report of a foreign issuerSep 16, 2024Current reportSEC
New Positive Efficacy Data for Efti in Head and Neck CancerSep 15, 2024ResultsASX
6-K · Report of a foreign issuerSep 9, 2024Current reportSEC
S&P DJI Announces September 2024 Quarterly RebalanceSep 6, 2024Other filingsASX
6-K · Report of a foreign issuerSep 3, 2024Current reportSEC
Appendix 4E & 2024 Full Year Statutory AccountsAug 30, 2024Annual reportASX
6-K · Report of a foreign issuerAug 20, 2024Current reportSEC
TACTI-003 data selected for oral presentation at ESMO 2024Aug 20, 2024Other filingsASX
6-K · Report of a foreign issuerAug 14, 2024Current reportSEC
First Participant Dosed in Phase I Study of IMP761Aug 13, 2024Other filingsASX
6-K · Report of a foreign issuerJul 31, 2024Current reportSEC
6-K · Report of a foreign issuerJul 23, 2024Current reportSEC
Successful Meeting with FDA on Phase III Design in NSCLCJul 21, 2024Operations updateASX
6-K · Report of a foreign issuerJul 17, 2024Current reportSEC
Regulatory Clearance received for Phase 1 trial of IMP761Jul 16, 2024Other filingsASX
6-K · Report of a foreign issuerJul 12, 2024Current reportSEC
Webcast to discuss data presented at ESMO Plenary SessionJul 11, 2024Operations updateASX
Positive results in TACTI-003 for 1L HNSCC cohort B patientsJul 11, 2024ResultsASX
6-K · Report of a foreign issuerJul 3, 2024Current reportSEC
6-K · Report of a foreign issuerJun 28, 2024Current reportSEC
Webcast slides for new Efti clinical data in 1st line HNSCCJun 26, 2024Other filingsASX
Positive topline results from ph2b in head & neck cancerJun 26, 2024Other filingsASX
6-K · Report of a foreign issuerJun 25, 2024Current reportSEC
6-K · Report of a foreign issuerJun 24, 2024Current reportSEC
Immutep completes underwritten retail entitlement offerJun 24, 2024FinancingASX
6-K · Report of a foreign issuerJun 5, 2024Current reportSEC
Immutep completes institutional pro-rata offer & placementJun 4, 2024FinancingASX
6-K · Report of a foreign issuerJun 4, 2024Current reportSEC
Immutep announces Ph 3 clinical trial collaboration with MSDJun 3, 2024Operations updateASX
Immutep Capital Raising PresentationJun 2, 2024FinancingASX
A$100 million fully underwritten equity raisingJun 2, 2024Other filingsASX
6-K · Report of a foreign issuerMay 15, 2024Current reportSEC
AIPAC-003 safety lead-in data presented at ESMO Breast 2024May 15, 2024Operations updateASX
6-K · Report of a foreign issuerMay 2, 2024Current reportSEC
Positive initial data in phase 2 Soft Tissue Sarcoma trialMay 1, 2024Operations updateASX
6-K · Report of a foreign issuerApr 30, 2024Current reportSEC
6-K · Report of a foreign issuerApr 24, 2024Current reportSEC
Positive preliminary topline results from TACTI-003 Cohort BApr 23, 2024Other filingsASX
6-K · Report of a foreign issuerApr 18, 2024Current reportSEC
CHDR to conduct first-in-human phase 1 trial of IMP761Apr 17, 2024Other filingsASX
6-K · Report of a foreign issuerMar 5, 2024Current reportSEC
First Clinical Data announced from 90mg Dosing of EftiMar 5, 2024Operations updateASX
6-K · Report of a foreign issuerFeb 29, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerJan 30, 2024Current reportSEC
6-K · Report of a foreign issuerDec 21, 2023Current reportSEC
PEI provides constructive feedback for ph3 lung cancer trialDec 20, 2023Other filingsASX
6-K · Report of a foreign issuerDec 7, 2023Current reportSEC
Immutep receives A$2.6 million French R&D Tax IncentiveDec 6, 2023FinancingASX
6-K · Report of a foreign issuerNov 9, 2023Current reportSEC
Immutep Completes Enrolment for TACTI-003 Phase IIb TrialNov 8, 2023Operations updateASX
6-K · Report of a foreign issuerNov 6, 2023Current reportSEC
Lead-in phase completed for ph2/3 trial in Breast CancerNov 5, 2023Operations updateASX
6-K · Report of a foreign issuerNov 3, 2023Current reportSEC
New Biomarker Data from TACTI-002 trial in 1st line NSCLCNov 2, 2023Operations updateASX
6-K · Report of a foreign issuerOct 31, 2023Current reportSEC
6-K · Report of a foreign issuerOct 25, 2023Current reportSEC
6-K · Report of a foreign issuerOct 24, 2023Current reportSEC
20-F · Annual reportOct 24, 2023Annual reportSEC
6-K · Report of a foreign issuerOct 24, 2023Current reportSEC
Immutep reports promising data from INSIGHT-003 trialOct 23, 2023Operations updateASX
Webcast slides for new Efti clinical data in 1st line NSCLCOct 22, 2023Operations updateASX
Excellent Overall Survival in Non-Small Cell Lung CancerOct 22, 2023Other filingsASX
6-K · Report of a foreign issuerOct 16, 2023Current reportSEC
Immutep announces publication of ESMO 2023 abstractsOct 15, 2023Other filingsASX
6-K · Report of a foreign issuerSep 21, 2023Current reportSEC
Commercial Scale Manufacturing of Efti for Clinical TrialsSep 20, 2023Other filingsASX
Appendix 4E & 2023 Full Year Statutory AccountsAug 29, 2023Annual reportASX
6-K · Report of a foreign issuerAug 1, 2023Current reportSEC
Immutep receives positive scientific advice from EMAAug 1, 2023Other filingsASX
6-K · Report of a foreign issuerJul 31, 2023Current reportSEC
6-K · Report of a foreign issuerJul 28, 2023Current reportSEC
1st Patient Dosed in Phase 2 Soft Tissue Sarcoma TrialJul 27, 2023Other filingsASX

This page holds 200 of 1,037 filings.

All of its filings on SEC EDGAR